Nasdaq
$2.00▲ 1.27%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $144.5MShares out 72.2M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
4- 9.16Pre-market26.09.16 22:268-KKey event#●●●#●●●
Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals hosted an Investor Day on September 16, 2026, to provide updates on the Phase 2 clinical trial of its Alzheimer's candidate, sabirnetug, and its next-generation Enhanced Brain Delivery (EBD) pipeline. The company expects to report topline results from the Phase 2 trial of sabirnetug in late 2026 and stated that its current cash resources are sufficient to fund operations into early 2027.…more
$2.00+1.27%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.12After-hours26.08.13 05:24S-8Offering
Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc. has filed a Form S-8 to register an additional 10,000,000 shares of common stock for issuance under its Amended and Restated 2021 Equity Incentive Plan, which was approved by stockholders on June 3, 2026. This registration brings the total number of shares authorized for issuance under the plan to 29,040,630, intended for employee equity compensation.…more
$2.00+1.27%vs prev closeView filingShare - 8.12After-hours26.08.13 05:1310-QEarnings
Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals (ABOS) amended and restated its 2021 Equity Incentive Plan, which was approved by shareholders on June 3, 2026. This amendment authorizes the issuance of up to 10 million additional shares of common stock, with total outstanding shares reaching 72,317,285 as of August 7, 2026.…more
$2.00+1.27%vs prev closeView filingShare
3 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoPre-market26.10.22 20:30#●●●#●●●
Acumen Pharmaceuticals to Present Phase 2 Alzheimer’s Trial Data at CTAD…more
Acumen Pharmaceuticals will present preliminary baseline data and patient experience insights from its Phase 2 ALTITUDE-AD trial at the upcoming CTAD conference. The company expects to release topline results for the sabirnetug study in late 2026.…more
$2.00+1.27%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 5d agoAfter-hours26.10.20 05:00
●●●●●●●● ●●●●● ●●●●●●
Acumen Pharmaceuticals will report its third-quarter financial results on October 26, 2026, followed by a conference call. This is a routine announcement regarding the earnings schedule and does not contain material financial data.…more
$2.00+1.27%vs prev close - 9.10After-hours26.09.11 05:00
●●●●●●●● ●●●●● ●●●●●●
Acumen Pharmaceuticals announced it will hold a virtual Investor Day on September 16, 2026, to discuss its business updates. This event is a standard corporate communication and does not provide immediate material impact on the stock price.…more
$2.00+1.27%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report